The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials

D. G. Bostwick, H. B. Burke, T. M. Wheeler, L. W.K. Chung, R. Bookstein, T. G. Pretlow, R. B. Nagle, R. Montironi, M. M. Lieber, R. W. Veltri, W. E. Grizzle, D. J. Grignon

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Surrogate endpoint biomarkers (SEBs) are needed in clinical chemoprevention trials to avoid the excessively long study periods and high costs associated with the use of cancer incidence reduction as an endpoint, particularly with relatively slow-growing tumors such as prostatic adenocarcinoma. SEBs should be directly associated with the evolution of neoplasia, and develop with high frequency in abnormal cells of susceptible individuals. If SEBs can be modified by a particular intervention regimen in short-term studies, the rationale for carrying out long-term studies may be strengthened. The consensus panel identified a small and manageable group of biomarkers measured in tissue or serum as the most promising in prostate cancer chemoprevention, including (1) prostate specific antigen (PSA); (2) morphometric markers, such as nuclear size and roundness; (3) proliferation markers, such as MIB-1 and PCNA; (4) nuclear DNA content (ploidy); (5) oncogene c-erbB-2 (HER-2/neu) expression; (6) angiogenesis; and (7) high-grade prostatic intraepithelial neoplasia (PIN). Information regarding many of these and other biomarkers is limited, calling for further investigation. Also, these factors, chosen chiefly for their proven or proposed utility as prognostic factors, may be less useful as SEBs. It was agreed that concurrent study of numerous markers rather than single markers allows comparison of their relative utility, including assessment of ease of quantitation and the sensitivity, specificity, and positive and negative predictive value.

Original languageEnglish (US)
Pages (from-to)283-289
Number of pages7
JournalJournal of Cellular Biochemistry
Volume56
Issue numberSUPPL. 19
StatePublished - Jan 1 1994

Fingerprint

Phase II Clinical Trials
Biomarkers
Screening
Adenocarcinoma
Chemoprevention
Proliferating Cell Nuclear Antigen
Prostate-Specific Antigen
Tumors
Prostatic Intraepithelial Neoplasia
Neoplasms
Tissue
Ploidies
Oncogenes
DNA
Prostatic Neoplasms
Cohort Studies
Clinical Trials
Costs
Costs and Cost Analysis
Sensitivity and Specificity

Keywords

  • Biomarkers
  • Chemoprevention
  • Premalignancy
  • Prostate cancer
  • Prostatic intraepithelial neoplasia
  • Risk stratification

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Bostwick, D. G., Burke, H. B., Wheeler, T. M., Chung, L. W. K., Bookstein, R., Pretlow, T. G., ... Grignon, D. J. (1994). The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. Journal of Cellular Biochemistry, 56(SUPPL. 19), 283-289.

The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. / Bostwick, D. G.; Burke, H. B.; Wheeler, T. M.; Chung, L. W.K.; Bookstein, R.; Pretlow, T. G.; Nagle, R. B.; Montironi, R.; Lieber, M. M.; Veltri, R. W.; Grizzle, W. E.; Grignon, D. J.

In: Journal of Cellular Biochemistry, Vol. 56, No. SUPPL. 19, 01.01.1994, p. 283-289.

Research output: Contribution to journalArticle

Bostwick, DG, Burke, HB, Wheeler, TM, Chung, LWK, Bookstein, R, Pretlow, TG, Nagle, RB, Montironi, R, Lieber, MM, Veltri, RW, Grizzle, WE & Grignon, DJ 1994, 'The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials', Journal of Cellular Biochemistry, vol. 56, no. SUPPL. 19, pp. 283-289.
Bostwick, D. G. ; Burke, H. B. ; Wheeler, T. M. ; Chung, L. W.K. ; Bookstein, R. ; Pretlow, T. G. ; Nagle, R. B. ; Montironi, R. ; Lieber, M. M. ; Veltri, R. W. ; Grizzle, W. E. ; Grignon, D. J. / The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. In: Journal of Cellular Biochemistry. 1994 ; Vol. 56, No. SUPPL. 19. pp. 283-289.
@article{ee511b13a79040f8afcf2bd3eb22c5ec,
title = "The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials",
abstract = "Surrogate endpoint biomarkers (SEBs) are needed in clinical chemoprevention trials to avoid the excessively long study periods and high costs associated with the use of cancer incidence reduction as an endpoint, particularly with relatively slow-growing tumors such as prostatic adenocarcinoma. SEBs should be directly associated with the evolution of neoplasia, and develop with high frequency in abnormal cells of susceptible individuals. If SEBs can be modified by a particular intervention regimen in short-term studies, the rationale for carrying out long-term studies may be strengthened. The consensus panel identified a small and manageable group of biomarkers measured in tissue or serum as the most promising in prostate cancer chemoprevention, including (1) prostate specific antigen (PSA); (2) morphometric markers, such as nuclear size and roundness; (3) proliferation markers, such as MIB-1 and PCNA; (4) nuclear DNA content (ploidy); (5) oncogene c-erbB-2 (HER-2/neu) expression; (6) angiogenesis; and (7) high-grade prostatic intraepithelial neoplasia (PIN). Information regarding many of these and other biomarkers is limited, calling for further investigation. Also, these factors, chosen chiefly for their proven or proposed utility as prognostic factors, may be less useful as SEBs. It was agreed that concurrent study of numerous markers rather than single markers allows comparison of their relative utility, including assessment of ease of quantitation and the sensitivity, specificity, and positive and negative predictive value.",
keywords = "Biomarkers, Chemoprevention, Premalignancy, Prostate cancer, Prostatic intraepithelial neoplasia, Risk stratification",
author = "Bostwick, {D. G.} and Burke, {H. B.} and Wheeler, {T. M.} and Chung, {L. W.K.} and R. Bookstein and Pretlow, {T. G.} and Nagle, {R. B.} and R. Montironi and Lieber, {M. M.} and Veltri, {R. W.} and Grizzle, {W. E.} and Grignon, {D. J.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "56",
pages = "283--289",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "SUPPL. 19",

}

TY - JOUR

T1 - The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials

AU - Bostwick, D. G.

AU - Burke, H. B.

AU - Wheeler, T. M.

AU - Chung, L. W.K.

AU - Bookstein, R.

AU - Pretlow, T. G.

AU - Nagle, R. B.

AU - Montironi, R.

AU - Lieber, M. M.

AU - Veltri, R. W.

AU - Grizzle, W. E.

AU - Grignon, D. J.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Surrogate endpoint biomarkers (SEBs) are needed in clinical chemoprevention trials to avoid the excessively long study periods and high costs associated with the use of cancer incidence reduction as an endpoint, particularly with relatively slow-growing tumors such as prostatic adenocarcinoma. SEBs should be directly associated with the evolution of neoplasia, and develop with high frequency in abnormal cells of susceptible individuals. If SEBs can be modified by a particular intervention regimen in short-term studies, the rationale for carrying out long-term studies may be strengthened. The consensus panel identified a small and manageable group of biomarkers measured in tissue or serum as the most promising in prostate cancer chemoprevention, including (1) prostate specific antigen (PSA); (2) morphometric markers, such as nuclear size and roundness; (3) proliferation markers, such as MIB-1 and PCNA; (4) nuclear DNA content (ploidy); (5) oncogene c-erbB-2 (HER-2/neu) expression; (6) angiogenesis; and (7) high-grade prostatic intraepithelial neoplasia (PIN). Information regarding many of these and other biomarkers is limited, calling for further investigation. Also, these factors, chosen chiefly for their proven or proposed utility as prognostic factors, may be less useful as SEBs. It was agreed that concurrent study of numerous markers rather than single markers allows comparison of their relative utility, including assessment of ease of quantitation and the sensitivity, specificity, and positive and negative predictive value.

AB - Surrogate endpoint biomarkers (SEBs) are needed in clinical chemoprevention trials to avoid the excessively long study periods and high costs associated with the use of cancer incidence reduction as an endpoint, particularly with relatively slow-growing tumors such as prostatic adenocarcinoma. SEBs should be directly associated with the evolution of neoplasia, and develop with high frequency in abnormal cells of susceptible individuals. If SEBs can be modified by a particular intervention regimen in short-term studies, the rationale for carrying out long-term studies may be strengthened. The consensus panel identified a small and manageable group of biomarkers measured in tissue or serum as the most promising in prostate cancer chemoprevention, including (1) prostate specific antigen (PSA); (2) morphometric markers, such as nuclear size and roundness; (3) proliferation markers, such as MIB-1 and PCNA; (4) nuclear DNA content (ploidy); (5) oncogene c-erbB-2 (HER-2/neu) expression; (6) angiogenesis; and (7) high-grade prostatic intraepithelial neoplasia (PIN). Information regarding many of these and other biomarkers is limited, calling for further investigation. Also, these factors, chosen chiefly for their proven or proposed utility as prognostic factors, may be less useful as SEBs. It was agreed that concurrent study of numerous markers rather than single markers allows comparison of their relative utility, including assessment of ease of quantitation and the sensitivity, specificity, and positive and negative predictive value.

KW - Biomarkers

KW - Chemoprevention

KW - Premalignancy

KW - Prostate cancer

KW - Prostatic intraepithelial neoplasia

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=0028692660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028692660&partnerID=8YFLogxK

M3 - Article

C2 - 7529857

AN - SCOPUS:0028692660

VL - 56

SP - 283

EP - 289

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - SUPPL. 19

ER -